Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections.

The estrogen receptor (ER) status and, to a lesser extent, progesterone receptor status have been recommended by recently published guidelines as important for routine prognostic and predictive evaluation of breast cancer. Although the clinical utility of ER status has been largely validated using biochemical ligand-binding assays such as the dextran-coated, charcoal ligand-binding assay, there has been the need to develop the ER immunocytochemical assay as a more accurate and practical alternative. In particular, ER status as determined on paraffin sections by immunocytochemical assay has been shown to be superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. The success of the paraffin-section assay is founded on two principles. The first relates to the advent of the heat-mediated, antigen-retrieval technique capable of restoring ER and progesterone receptor antigenicity in routinely prepared diagnostic formalin-fixed, paraffin-embedded tissue sections. The second is associated with the capacity for this substrate to provide more reliable and reproducible semiquantitative assessment of ER status in morphologically better-preserved tissue used routinely for histopathological diagnosis. The aim of this chapter is to describe the methodology currently used for optimal reproducible demonstration, scoring, and assessment of ER status in paraffin wax-embedded tissue sections in relation to the management of breast cancer in a routine or clinical-trial setting.

[1]  J. Coindre,et al.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.

[2]  J. Jacquemier,et al.  Estrogen receptor immunocytochemical assay (ER-ICA): computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas. , 1986, Cancer research.

[3]  R. Ravid,et al.  Activation of the human supraptic and paraventricular nucleus neurons with aging and in Alzheimer's disease as judged from increasing size of the Golgi apparatus , 1993, Brain Research.

[4]  M Bibbo,et al.  Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system. , 1987, Analytical and quantitative cytology and histology.

[5]  R. Blamey Guidelines on endocrine therapy of breast cancer EUSOMA. , 2002, European journal of cancer.

[6]  A. Serizawa,et al.  Heat‐induced antigen retrieval of proliferating cell nuclear antigen and p53 protein in formalin‐fixed, paraffin‐embedded sections , 1994, Pathology international.

[7]  S. Pileri,et al.  Antigen retrieval techniques in immunohistochemistry: comparison of different methods , 1997, The Journal of pathology.

[8]  B. Jasani,et al.  Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.

[9]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.

[10]  O. Petersen,et al.  Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. , 1987, Cancer research.

[11]  P. Chambon,et al.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer. , 1991, Cancer research.

[12]  A. Howell,et al.  Dissociation between steroid receptor expression and cell proliferation in the human breast. , 1997, Cancer research.

[13]  L. Bobrow,et al.  Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. , 2001, American journal of clinical pathology.

[14]  J. Sloane,et al.  Oestrogen receptor expression in the normal and pre‐cancerous breast , 1999, The Journal of pathology.

[15]  S R Shi,et al.  DEVELOPMENT OF AN OPTIMAL PROTOCOL FOR ANTIGEN RETRIEVAL: A ‘TEST BATTERY’ APPROACH EXEMPLIFIED WITH REFERENCE TO THE STAINING OF RETINOBLASTOMA PROTEIN (pRB) IN FORMALIN‐FIXED PARAFFIN SECTIONS , 1996, The Journal of pathology.

[16]  N. Piggott,et al.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. , 1991, British Journal of Cancer.

[17]  A. Howell,et al.  Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast , 1991, International journal of cancer.

[18]  D. Barnes,et al.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.

[19]  D. Sgoutas,et al.  Immunohistochemical progesterone receptor assay. Measurement by image analysis. , 1991, American journal of clinical pathology.

[20]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D H Wright,et al.  Tissue preparation for immunocytochemistry. , 1997, Journal of clinical pathology.

[22]  J. Demongeot,et al.  Image cytometry of estrogen receptors in breast carcinomas. , 1988, Cytometry.

[23]  S. Martino,et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Immunohistochemical determination of nuclear antigens by colour image analysis: application for labelling index, estrogen and progesterone receptor status in breast cancer. , 1994, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[25]  Clive R. Taylor,et al.  Standardization of immunohistochemistry based on antigen retrieval technique for routine formalin-fixed tissue sections , 1998 .

[26]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  I. Ellis,et al.  Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy , 2004, Breast Cancer Research and Treatment.